Lantern Pharma (LTRN) AI Stock Analysis

• Market Cap: $32.99M
• Dividend Yield: N/A
• Average Volume (3M): 51.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: N/A
• EPS Growth: 1.18%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 11,184,423
• 10 Day Avg. Volume: 55,651
• 30 Day Avg. Volume: 51,269
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.93
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -339.51
• Enterprise Value/Ebitda: -1.05
• 1Y Price Target: $25.00
• Price Target Upside: 727.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $3.00 ▼(-0.66% Downside)

The score is primarily held down by weak financial performance (no revenue, persistent losses, and significant cash burn with a shrinking equity base). Offsetting this, the latest earnings call cited notable clinical/regulatory milestones and AI platform progress, while technicals are neutral-to-slightly positive but not strong enough to outweigh financing and profitability risks.

Positive Factors

Clinical trial validation (LP-184 Phase Ia)

Achieving all primary endpoints with a 48% clinical benefit rate materially de-risks LP-184 relative to early-stage peers. Durable impact: positive human efficacy signals improve prospects for later-stage trials, partnering interest, and regulatory engagement, raising program success probability.

RADR AI platform commercial readiness

A commercially ready, modular AI platform creates a structural advantage by enabling licensing, services, and partnerships that can generate recurring non-drug revenue. Over months, platform monetization can diversify cash sources and enhance trial efficiency and target selection.

Low financial leverage reduces solvency risk

Very low debt limits fixed obligations and preserves optionality on timing and structure of future financings or partnerships. Structurally, low leverage reduces bankruptcy risk and gives management flexibility to pursue clinical or platform milestones without debt-driven constraints.

Negative Factors

Pre-revenue with persistent net losses

Remaining pre-revenue means Lantern lacks product-derived cash flow and must fund operations externally. Persistently large net losses imply continued financing dependence, constrain reinvestment capacity, and lengthen the time to sustainable margins or self-funding business model.

Heavy cash burn and limited runway

Sustained negative operating cash flow and limited cash to Q3 2026 create a structural funding cliff. This forces near-term capital raises that can dilute shareholders, limit the company's ability to run multiple trials, and compress optionality for partnering or commercialization pacing.

Shrinking equity base increases financing risk

A materially reduced equity base signals repeated financing or valuation erosion, leaving less balance-sheet cushion for future adverse outcomes. Structurally this elevates dilution risk, constrains negotiating leverage with partners, and raises the stakes of near-term clinical and funding milestones.

Lantern Pharma Business Overview & Revenue Model

Company Description

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

How the Company Makes Money

Lantern Pharma generates revenue primarily through the development and commercialization of its drug candidates. The company uses its proprietary RADR platform to identify biomarkers and genetic signatures that can predict patient response to its drug candidates, thereby reducing time and cost associated with drug development. Revenue streams include out-licensing partnerships, collaborations with pharmaceutical companies, and potentially, future sales of approved drugs. These partnerships often involve milestone payments, royalties, and shared development costs, which are significant contributors to the company's earnings. As Lantern Pharma advances its drug pipeline and secures additional partnerships, these factors are expected to drive financial growth.

Lantern Pharma Financial Statement Overview

Summary

Pre-revenue with sizable ongoing losses and heavy, worsening cash burn (TTM operating cash flow about -$16.9M). Low leverage reduces solvency risk, but the equity base has materially declined over time, increasing financing/runway dependence.

Income Statement

The company is still pre-revenue (revenue is $0 in both TTM (Trailing-Twelve-Months) and recent annual periods), so losses are driven by operating spend rather than sales. Net losses remain large (about -$18.9M in TTM), and profitability has not stabilized—losses have generally widened versus 2020, indicating rising cost intensity over time. Strength: the loss profile is fairly consistent with an R&D-stage biotechnology model, but the lack of revenue and persistently deep negative earnings keep the income statement score low.

Balance Sheet

Leverage is very low (debt-to-equity ~0.01 in both TTM (Trailing-Twelve-Months) and 2024), which reduces solvency risk and provides financial flexibility. However, the equity base has declined meaningfully over time (from ~$71.6M in 2021 to ~$9.6M in TTM), reflecting ongoing losses and potential dilution/valuation compression. Return on equity is sharply negative (near -1.0 in TTM), highlighting that the balance sheet is being consumed by operating deficits despite low debt.

Cash Flow

Cash burn is heavy and persistent: operating cash flow is negative across all periods and is -$16.9M in TTM (Trailing-Twelve-Months), with free cash flow also negative at roughly the same level. Free cash flow deterioration versus the prior year is pronounced (TTM free cash flow growth -5.666), signaling accelerating cash use. Strength: free cash flow roughly tracks net loss (free cash flow to net income ~1.0), suggesting losses are largely cash-backed rather than driven by large non-cash addbacks, but the magnitude and trajectory of burn are the key weakness.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-59.90K	0.00	-174.84K	0.00	0.00	0.00
EBITDA	-19.41M	-22.20M	-15.79M	-14.42M	-12.58M	-5.90M
Net Income	-18.92M	-20.78M	-15.96M	-14.26M	-12.36M	-5.91M
Balance Sheet
Total Assets	13.63M	25.57M	43.65M	58.84M	73.95M	20.36M
Cash, Cash Equivalents and Short-Term Investments	12.36M	24.01M	41.30M	55.20M	70.73M	19.23M
Total Debt	93.95K	243.66K	234.47K	52.89K	204.95K	108.50K
Total Liabilities	4.04M	4.38M	2.74M	2.80M	2.38M	660.84K
Stockholders Equity	9.59M	21.19M	40.91M	56.04M	71.57M	19.70M
Cash Flow
Free Cash Flow	-16.86M	-17.83M	-14.37M	-12.80M	-10.61M	-5.67M
Operating Cash Flow	-16.86M	-17.81M	-14.35M	-12.77M	-10.59M	-5.65M
Investing Cash Flow	16.21M	3.37M	-930.21K	179.27K	-19.53M	-16.14K
Financing Cash Flow	971.78K	66.71K	-500.00K	-2.18M	63.42M	23.66M

Lantern Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LTRN, the sentiment is Negative. The current price of 3.02 is below the 20-day moving average (MA) of 3.33, below the 50-day MA of 3.41, and below the 200-day MA of 3.75, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 36.78 is Neutral, neither overbought nor oversold. The STOCH value of 14.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LTRN.

Lantern Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNXT	51 Neutral	$35.35M	-2.71	-146.61%	―	―	37.89%
LTRN	50 Neutral	$32.99M	-1.68	-104.58%	―	―	1.18%
SKYE	49 Neutral	$27.89M	-0.67	-94.31%	―	―	-53.18%
MDCX	45 Neutral	$28.88M	-0.54	-2237.54%	―	―	-55.95%
BCAB	44 Neutral	$13.44M	-0.18	―	―	-100.00%	32.37%
MAIA	44 Neutral	$79.25M	-2.88	-2691.06%	―	―	44.50%

Lantern Pharma Corporate Events

Lantern Pharma Showcases AI Platform for Rare Cancers

On January 22, 2026, Lantern Pharma hosted an event where it used a prepared presentation to support discussions and a live demonstration of its initial AI tools and multi-agent system designed for rare cancer applications. The event, and the associated presentation, underscored the company’s operational focus on integrating advanced AI technologies into oncology research for rare cancers, signaling continued efforts to position itself as a technology-driven player in precision cancer therapeutics and to engage stakeholders around its emerging AI platform capabilities.

The most recent analyst rating on (LTRN) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.

Lantern Pharma Achieves Key Milestones in Q3 2025

Lantern Pharma reported its third quarter 2025 financial results and business updates, highlighting significant progress in clinical validation, regulatory advancements, and strategic momentum. The company achieved all primary endpoints in its LP-184 Phase 1a clinical trial, showing a 48% clinical benefit rate in cancer patients, and received FDA guidance for its pediatric CNS cancer trial. The AI platform’s commercial readiness was demonstrated, and disciplined capital management was maintained, positioning Lantern Pharma for future growth in oncology indications.

The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.